Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
July 31, 2025
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everyone, and thanks for joining Teleflex Inc.'s Second Quarter 2025 Earnings Conference Call this morning. You can find the press release and slides that go with this call on our website, teleflex.com. Just a note that a replay will also be accessible on our website. For those who want to listen to the replay, please check this morning's press release for the details. On the call with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and John Deren, our Executive Vice President and Chief Financial Officer. Liam and John will give prepared remarks, and after that, we'll open things up for Q&A. Before we get started, I want to note that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. We want to caution you that these statements are forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include, but are not limited to, those referenced in today's press release as well as our filings with the SEC, including our Form 10-K, which you can access on our website; now I'll hand the call over to Liam for his remarks.
Liam Kelly
executiveThank you, Larry, and good morning to all of you. During today's call, we'll go over the results for the second quarter, share a strategic update, walk through commercial highlights and finish with our revised financial guidance for 2025. As a note, growth in revenue year-over-year on a constant currency basis is adjusted to account for the impact of the Italian measure, which was recorded during the second quarter of 2024. Our results for the second quarter show the progress we continue to make as we strive to deliver operational excellence and boost value creation throughout our business. Revenues in the second quarter came to $780.9 million, which is a rise of 4.2% year-over-year on a GAAP basis and 1% higher on an adjusted constant currency basis; this outcome surpassed the top end of the $769 million to $777 million guidance we gave previously. Adjusted earnings per share for the second quarter totaled $3.73, up 9.1% year-over-year. Let's now take a closer look at our second quarter revenue results. I'll start by reviewing revenues for our geographic segments in the second quarter. Every growth rate I mention is on an adjusted constant currency basis, unless I say otherwise. Revenues in the Americas reached $525.7 million, up 2% year-over-year and consistent with expectations. Growth in revenue for the quarter came from strength in intra-aortic balloon pumps and was partly offset by declines in OEM and ongoing difficulties in UroLift. EMEA revenues of $166.2 million fell 2.1% year-over-year and came in somewhat softer than anticipated. In the quarter, we experienced strength in our Interventional business, which was offset by our Anesthesia business, including a difficult year-over-year comparison in military orders. Now to Asia. Revenues totaled $89 million, up 1.2% year-over-year and consistent with what we expected. Growth in revenue came from strength in Southeast Asia, India and Japan, which was partly offset by the volume-based procurement dynamics we previously announced affecting our China business. As anticipated, we saw revenue improve sequentially in China during the second quarter and expect further improvement throughout the rest of 2025. Let's now turn to discussing our second quarter revenues by global products category. Comments on global product category growth for the second quarter will also be on a year-over-year adjusted constant currency basis. Beginning with Vascular Access. Revenue rose 1.4% year-over-year to $185.5 million. The quarter was led by year-over-year growth in PICCs, which grew at a double-digit rate, along with a solid performance in EZ-IO. Looking ahead, we anticipate growth will accelerate in the second half of the year. Moving to Interventional. Revenue came to $170 million, up 19.3% year-over-year. The robust performance for the quarter was led by growth drivers including intra-aortic balloon pumps and catheters, OnControl, complex catheters and right heart catheters. Now to Anesthesia. Revenues declined 7.6% year-over-year to $96.4 million. Among our largest product categories, hemostatic products and LMA single-use masks achieved growth in the quarter but were mainly offset by a difficult comparison in military orders and pressure on airway products. In our Surgical business, revenue was $114 million, up 1.4% year-over-year. The fundamental momentum in our main surgical segment stayed robust, though it was partly counterbalanced by the anticipated effect of volume-based purchasing in China. Mid-single-digit expansion occurred during the quarter in our North American surgical operation, which volume-based procurement does not touch. Turning to Interventional Urology, we recorded $76.4 million in revenue, which marks an 8.3% decline compared with the same period last year. Barrigel delivered impressive double-digit gains, yet UroLift remains under pressure. OEM revenue fell 12.4% from a year earlier, landing at $78.7 million, which matched what we had anticipated. A lost customer contract that we previously made public, along with ongoing inventory management by customers, weighed on the second quarter. During Q2, as expected, revenue improved sequentially, and we still expect a larger revenue contribution across the latter six months of 2025 compared with the first six months. Other revenues for the second quarter rose 3.5% year-over-year, reaching $59.9 million. Urology Care drove this result, especially intermittent catheters. That wraps up what I have to say regarding revenue performance in the second quarter. Now for a strategic update. We are proactively pursuing actions to unlock value inside our company. Toward that end, we keep advancing the separation of Teleflex that we made public in February. Following the separation, both businesses will be optimally situated going forward, benefiting from sharper strategic focus, less complex operating structures, a more efficient manufacturing footprint, and capital allocation approaches individually crafted to match each one's distinct growth philosophy and goals. Simultaneously, we are also exploring, in parallel, a possible divestiture of NewCo. As was covered during our Q1 earnings call, a substantial number of inbound indications of interest in buying NewCo have come our way. Since that time, consistent with our dedication to getting the most value for shareholders, our Board and management team have been diligently assessing a potential NewCo sale. As a progress report, preliminary discussions have taken place with numerous prospective purchasers. The volume and caliber of interested parties keeps making a strong impression on us. We will share updates with the investment community regarding our advancement along these parallel tracks when it is suitable to do so. Crucially, our guiding principles remain centered on extracting maximum shareholder value throughout this process. If a sale were to be finalized, our present plan is to direct the proceeds toward a combination of debt reduction and capital returned to shareholders. We will keep acting in the best interests of our company and its shareholders as we proceed through this process. Shifting to our approach for capital allocation. On June 30, the day our third quarter began, we were delighted to finalize the purchase of substantially all of BIOTRONIK's Vascular Intervention business, with a net initial upfront cash outlay of EUR 704 million. Within our company, the Teleflex Interventional portfolio has served as a growth and innovation cornerstone for a long time; with the chance to generate sustainable revenue growth and enhance margins, acquiring Vascular Intervention forms a critical piece of our value creation strategy, allowing us to build further on this solid base. We anticipate that our combined Interventional business will bring in $800 million plus in yearly revenues. The portfolio of products we've acquired features a wide range of vascular intervention devices, including drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, and balloon catheters. Our belief is that this acquisition will strengthen our worldwide footprint in the cath lab, broaden our array of innovative technologies, and boost patient care. Buying the Vascular Intervention business will additionally give Teleflex a chance to put money into and grow the clinical trial program for Freesolve, a sirolimus eluting resorbable metallic scaffold technology. Freesolve's pairing of temporary scaffolding with drug delivery is expected to tackle the present shift in interventional cardiology and endovascular procedures toward leaving less permanent hardware behind. We likewise perceive Freesolve's capacity to tackle the shortcomings of earlier polymeric resorbable scaffolds, delivering faster absorption, thinner struts, and metallic mechanical performance. Freesolve obtained a CE Mark in February of 2024 and is indicated for treating de novo coronary artery lesions. The European pivotal BioMag 2 study is presently running ahead of schedule, with over 800 patients enrolled out of the 2,000 patients total. We intend to launch the BioMag 3 U.S. pivotal study in the months ahead. The U.S.
Liam Kelly
executiveThe design of the study has been finalized, and together with the Scientific Steering Committee, we're beginning to enroll top interventional cardiology programs and investigators throughout the United States. As we mentioned in our July 1 press release about completing the acquisition, we anticipate the products we acquired will bring in EUR 177 million, or $204 million, during the second half of 2025. To be specific, we expect EUR 86 million in acquisition revenue in the third quarter and EUR 91 million in the fourth quarter. Starting in 2026, we anticipate that sales from the acquired products will produce annual constant currency revenue growth of 6% or higher; we also said in our July 1 announcement that, aside from nonrecurring purchase accounting items and other costs tied to the acquisition and integration, we expect the deal to add roughly $0.10 to our adjusted earnings per share in the first year of ownership, with growing accretion after that. Now for a few commercial and clinical updates. Let's begin with our Vascular business; we recently shared results from a new multinational study showing the efficacy of Arrow chlorhexidine-impregnated CVCs in ICU patients. The analysis in that study showed a statistically significant 70.5% decrease in CLABSIs among patients who received the impregnated antimicrobial catheters. Despite the fact that this patient cohort had longer average ICU stays and higher device utilization ratios, which point to frequent and prolonged use, infections were still significantly lower. That highlights the possible advantage of the antimicrobial technology even for high-risk patients. In addition, using chlorhexidine-impregnated CVCs was tied to a reduced incidence of infection-causing pathogens, such as gram-negative and gram-positive bacteria and fungi. Now to our Surgical business; we keep building out our foundation of clinical data supporting the Titan SGS stapler as safe and effective for patients having laparoscopic sleeve gastrectomy. In May, we announced that a retrospective study had been published, covering 257 patients between 2016 and 2023 who had sleeve gastrectomy. The study found that at 1 year after the procedure, compared with traditional surgical staplers, fewer patients in the Titan SGS stapler group reported GERD, and fewer patients in the Titan SGS stapler group developed de novo GERD, with both results being statistically significant. In addition, more patients in the TITAN SGS stapler group who had GERD before the procedure experienced resolution of this condition than patients in the traditional surgical stapler group. Importantly, the improvements in GERD outcomes associated with the Titan SGS Stapler came without a significant difference in weight loss at 1 year between the 2 groups. This study also found that the Titan SGS stapler allowed for a shorter average hospital length of stay than traditional surgical staplers. As the only stapler offering a 23-centimeter staple line, the industry's longest continuous staple cut line, the Titan SGS stapler is built to create an ideal tubular surgical sleeve anatomy; that means a consistent shape, without kinks, twists, or spirals, which improves the potential to resolve GERD and nausea. Our attention will stay on backing the Titan SGS stapler by broadening the clinical evidence behind it. When it comes to reimbursement, the centers for Medicare and Medicaid Services has put out its proposed rule for 2026 covering payment for UroLift and Barrigel in the physician's office as well as ASC hospital outpatient care settings. Taking the 2026 proposed rules as a whole, should they take effect pretty much as described, that would represent a favorable development for the reimbursement landscape. That wraps up what I had prepared to say; at this point I'd like to hand things over to John, who will walk through our second quarter financial results in greater detail. John?
John Deren
executiveThank you, Liam, and good morning. Now that we've gone over how the company performed on revenue, I'd like to start with margins. Adjusted gross margin for the quarter came in at 59.7%, which represents a decline of 110 basis points compared with the same period last year. That result matched what we had anticipated, and the main drivers were ongoing inflationary pressure tied to macroeconomic conditions — particularly in labor and raw materials — along with higher costs for logistics and distribution and an unfavorable mix of products, though these were partly offset by movements in foreign currency exchange rates. In the second quarter, adjusted operating margin reached 26.9%. On the earnings call, management noted that the 20 basis point gain versus the previous year beat what they had anticipated, because the company offset the gross margin pressures experienced a year ago by keeping a tight rein on operating expenses, along with a helpful lift from currency movements. For the second quarter, adjusted net interest expense totaled $19.9 million, a slight increase from $19.4 million in the prior period. The increase compared with last year is mostly attributable to a higher average level of debt carried during the period, partially offset by lower rates on floating rate borrowings. The adjusted tax rate in the second quarter of 2025 was 13.1%, compared with 12.3% the year before. The increase relative to last year is driven primarily by additional costs tied to the implementation of Pillar 2 tax reform. On the bottom line, adjusted earnings per share for the second quarter was $3.73. The 9.1% year-over-year gain comes primarily from higher adjusted operating income, a reduced share count and a favorable foreign exchange benefit. Now I'll shift to a few balance sheet and cash flow items. Cash flow from operations over the 6 months was $81.2 million, compared with $204.5 million in the same period a year ago. The $123.3 million decrease came primarily from unfavorable working capital changes, which included payments for tariffs that were recently enacted; the year-over-year change also reflects payments tied to the proposed separation, payments for due diligence and transition planning costs related to the Vascular Intervention acquisition, as well as outflows for cloud computing arrangement expenditures as part of our ongoing development of our new ERP solution. Turning to the balance sheet: at the close of the second quarter, our balance of cash, cash equivalents and restricted cash equivalents was $283.9 million, down from $327.7 million as of year-end 2024. Net leverage at quarter end was roughly 1.8x, and 2.6x on a pro forma basis for the Vascular Intervention acquisition. Let's move on to the updated outlook we're providing for 2025. With the Vascular Intervention acquisition having closed on June 30, our expectation now is that total growth on a constant currency basis for 2025 will land somewhere between 7.7% and 8.7%, which is up from the 1% to 2% we had guided previously. The 2025 constant currency revenue growth figure rests on the same assumptions behind our prior outlook, along with an additional roughly $204 million in revenue that we estimate will come from the Vascular Intervention acquisition in the back half of the year; foreign exchange is now projected to help us by $26 million, amounting to a tailwind of about 85 basis points to GAAP revenue growth for 2025. Previously, we had forecast a headwind of about $5 million, equal to 17 basis points, for 2025 — that is the comparison here. With the updated foreign exchange guidance, an average euro rate of roughly $1.15 is being assumed for the second half of 2025. GAAP revenue growth for 2025 is now expected to land between 9% and 10%, an increase from the 1.3% to 2.3% range we had guided before, equivalent to $3.322 billion to $3.352 billion in dollar terms. Built into the 2025 outlook are our prior assumptions, the revised foreign exchange rates, and what the Vascular Intervention acquisition will contribute. The year-over-year growth rate takes into account the $13.8 million effect from the Italian measure during the second quarter of 2024. On the tariff front, things remain quite dynamic and may change once more over the coming months. Significant ambiguity persists regarding how the administration's tariff policy will be positioned, when it will take effect and how large it will be, along with the potential consequences of countermeasures from other nations. Consistent with the approach we outlined on our first quarter earnings call, our guidance reflects only those tariffs already in force, such as reciprocal rates applied to specific countries and the treatment of certain exemptions — chiefly in Mexico — that are linked to existing USMCA rules and regulations. Tariffs not yet put in place are excluded from the outlook. Should anything change down the road, the expected effect on our adjusted EPS for 2025 could look different. Our current projection for the tariff hit in 2025 is about $29 million, which works out to $0.55 per share. That's down from what we previously expected — $55 million, or $1.05 per share. What's behind the smaller anticipated tariff impact for 2025? A combination of shifts in tariff rates, mostly involving China, plus the early gains we're seeing from stepped-up mitigation efforts. We expect even more opportunities as the back half of 2025 unfolds. We're still aggressively looking at ways to reduce how much tariffs cost us in 2025 — that includes fine-tuning our supply chain, raising the share of USMCA compliant products in our mix, since those get tariff waivers when they're assembled in Mexico and Canada with U.S. components, and keeping a tight, disciplined grip on our spending. Since the previous time we reported earnings, we have moved forward on raising the share of products that qualify under USMCA and come into the United States from our plant in Mexico. On top of that, as contracts reach their renewal dates, we will start putting higher customer prices into effect. Also, when building your models, please take these points into account: our 2025 adjusted gross margin guidance is going up, and the new range is 58.75% to 59.5%, which works out to a 50 basis point lift at both the bottom and the top of that range. What is mainly behind this higher 2025 gross margin guidance figure is tariffs coming in lower than we had expected, with an unfavorable foreign exchange effect partly canceling that out. We're looking for adjusted operating margin between 24.5% and 25%. At the bottom of that range, that's 10 basis points lower than what we told you before. In our updated outlook, tariffs are coming in better than we expected, which helps, but that benefit is partly canceled out by added costs from the Vascular Intervention acquisition and by currency headwinds that went against us. Turning to below-the-line items: for 2025, net interest expense should be roughly $95 million, compared with the $75 million we had previously forecast. Most of that increase in net interest expense comes from the financing we put in place for the Vascular Intervention deal. On taxes, we've tightened up our assumption for 2025, and the rate we now anticipate is 13.25%, compared with the 13.5% we had before. Now on to adjusted earnings per share. We're taking both the bottom and top ends of our 2025 guidance up by $0.70, and $0.50 of that comes from the tariff impact being smaller than expected. Even though buying the Vascular Intervention business should be a touch dilutive in 2025, we believe operational performance will let us offset whatever negative effect shows up in adjusted EPS. So our 2025 adjusted earnings per share is now projected at $13.90 to $14.30. In the third quarter, adjusted constant currency growth should land between 15% and 16.5%, and that figure leaves out a foreign exchange gain of roughly $8 million. Just to remind everyone, the third quarter revenue outlook factors in $99 million of revenue from the Vascular Intervention acquisition. That wraps up what I had prepared, so I'll hand the call back to Liam now for his closing comments.
Liam Kelly
executiveThank you, John. To wrap up, I want to point out three main messages from Q2 of 2025. To start, we're still achieving meaningful strides when it comes to carrying out our plan, and our second-quarter sales came in higher than the top end of the guidance range we provided; on top of that, we feel good about our adjusted operating margin along with adjusted earnings per share. Next, we closed the purchase of the Vascular Intervention business, and integration work is now underway. We plan to hold a virtual investor event during the fall that will center on the Vascular Intervention business, highlighting the strategic rationale, the broad coronary and peripheral product lineup, and the clinical trial pathway for the Freesolve bioresorbable scaffold. Finally, we stay sharply focused on managing the things within our control throughout the company as we keep pushing our strategic goals forward. We're centered on improving how we execute operationally, bringing the business back to growth, and reinforcing our varied product portfolio so we can serve our customers better. We're also continuing to move ahead with the separation of Teleflex, guided by our principles, which aim to maximize shareholder value throughout this effort. That's everything I had prepared to say. At this point, I'd like to hand the call back to the operator so we can begin Q&A.
Matt Taylor
analystSo I actually had a couple. Could you give us additional detail on how the guidance bridge breaks down across tariffs, FX, and business outperformance? And congratulations on getting the BIOTRONIK deal closed. I was simply hoping you might help us grasp, just roughly, what the outlook is for that business and how it grows organically?
Liam Kelly
executiveAll right. I'll take — thank you, Matt. I'll take the BIOTRONIK Vascular Interventions business, and I'll have John take the beat and break it into operational and tariffs. So to begin, regarding the BIOTRONIK business, what we expect for organic growth in that business across the second half of the year is mid-single digits over that period. That represents the entire growth on that $204 million in the back half of the year, or the EUR 177 million, Matt. Our outlook for the business beginning in 2026 hasn't shifted at all. We continue to anticipate that the BIOTRONIK Vascular Interventions business will grow 6% or better; and John, would you mind covering the mix of the EPS business?
John Deren
executiveAs you can see, our operational results during Q2 were quite solid. A portion of that will extend into the latter six months, approximately $0.20, and that also accounts for whatever dilution BIOTRONIK brings. On tariffs, about 50% — excuse me, $0.50 across the full year. Then with foreign exchange on the negative side, tax negative, and shares on the positive side, those basically cancel one another out.
Liam Kelly
executiveLet me jump in here as well, Matt — regarding that $0.50, a substantial portion of it, somewhere between $0.45 and $0.47, originates from China. On top of that, we've achieved certain gains related to USMCA; in addition, there's been operational effort carried out quietly on our end to strengthen where we stand as a company when it comes to tariffs.
Jayson Bedford
analystI appreciate the information you provided. Since you shared quite a few figures, I'd rather not push too hard with this, but could you give me an approximate split for the growth of RemainCo versus NewCo? I'm uncertain whether we have sufficient data to work that out completely.
Liam Kelly
executiveFor the quarter, yes, I can. I'm able to provide a breakdown for RemainCo, and nothing about our outlook for RemainCo or its growth picture for the year has changed. Our expectation remains that it will land in the upper 5s, and excluding the effect of volume-based procurement during the second quarter, it fell within the mid-single-digit range, Jayson.
Jayson Bedford
analystAlright, that is useful. And you did briefly mention this, though interventional performed really well. Could you perhaps discuss how sustainable this kind of expansion is?
Liam Kelly
executiveSure; Interventional certainly enjoyed a solid, robust quarter. Clearly, balloon pumps achieved some very robust double-digit expansion and matched what we had anticipated. The outperformance within Interventional, in fact, came from OnControl as well as complex catheters, and our expectation remains that this segment will expand at a high single-digit to low double-digit rate across the entirety of 2025.
Anthony Petrone
analystCongratulations on the strides you've made with BIOTRONIK and the movement toward a deal involving NewCo. Perhaps regarding NewCo in particular, a sale as opposed to a spin, you're talking with a number of strategics. Liam, maybe just a bit about timing — clearly you're weighing every angle here — but anything you can share regarding timing on the decision-making process for NewCo would be useful. Then perhaps regarding the BIOTRONIK addition, the quarterly cadence of that business, maybe take us through the seasonality a little; my expectation would be that 3Q is somewhat more modest than 4Q. And your initial thinking on revenue synergies, particularly for that business alongside the existing Teleflex portfolio.
Liam Kelly
executiveAll right, Anthony, I appreciate those questions. Let me start with the sale versus spin topic and the timing. When it comes to when a spin might happen, nothing has shifted in our view. If we do decide to go the spin route, it would occur in mid-2026. Pinpointing when a sale could take place is something I find hard to do. That said, here's my perspective, Anthony: while we continue looking at every possibility, what matters most to us is delivering the greatest possible value to shareholders. And as I said during my prepared remarks, we've come a long way. Holding all those initial meetings with prospective buyers as part of the sales process — reaching that stage wouldn't have been possible if we hadn't moved forward on certain key deliverables. Take, for instance, wrapping up the quality of earnings work alongside the forward-looking view — both of which are prerequisites whether we pursue a sale or a spin. Beyond that, there's preparing the data room, pinpointing the internal leaders who will head up the management presentations, and naturally, assessing and sizing up the transition assistance required, plus securing a large batch of NDAs before those early get-togethers. That groundwork ought to accelerate things as we move into the second stage, the due diligence portion. As for how I feel about it, I'm still quite heartened and struck by how many parties are interested and how strong their caliber is — and that pattern is holding steady. Yes, Anthony, we intend to keep the due diligence process going through the third quarter, and should the sale go through, we'll of course keep everyone in the investment community informed along the way. On your second point, which was about BIOTRONIK and how the revenue is paced, you're right on target, and our guidance shows that, as you can tell. For Q3, we've included $99 million tied to BIOTRONIK. Then for Q4, the figure we've included for BIOTRONIK is $105 million, bringing the combined amount to $204 million. That gives you the typical cadence you'd see in any interventional business. On the synergies front, as I mentioned a bit earlier, BIOTRONIK will expand at a mid-single-digit pace, and we continue to anticipate growth of 6% or higher starting in 2026. Part of this comes from combining the two portfolios. There are two dimensions to that, Anthony. First, you have the question of accessing the cath lab — because the BIOTRONIK VI team throughout North America is not quite as big as Teleflex, so for them, gaining cath lab access is fairly difficult. But once you combine both organizations, access gets much easier; that ought to really help in bringing several of these portfolios together. Beyond that, certain organic synergies exist within the portfolio. Let me offer just a pair of illustrations. Within that cath lab, complex catheters make up the largest share of what we offer; so what purpose do complex catheters serve? They provide a route into the cartridge coronary arteries. What's the reason for obtaining that route? It's because you intend to place either a bare metal stent or a drug-eluting stent. Consequently, merging those two will certainly benefit the combination. The second illustration concerns perforations. Whenever a perforation occurs and mishaps arise during any procedure, the initial action required, the two combined offerings in this space that Teleflex currently possesses and, following the merger with the BIOTRONIK VI business, we shall become the leading participant here. Thus the ringer catheter gets deployed at the outset so the procedure can keep going. After that, the PK for pyros gets deployed to seal up to perforation. As a result, we could lock down this specialized segment of the worldwide market for Teleflex by joining these offerings; those are merely a couple of brief illustrations, Anthony, showing how this portfolio will function remarkably well in unison; and we eagerly anticipate holding an Investor Day to lay this out and convey our enthusiasm from Wall Street regarding why this represents an excellent match for Teleflex.
Shagun Singh Chadha
analystI suppose I have a few questions for clarification. First, regarding the EPS beat in Q2, could you help us break down how much came from tariffs as opposed to business outperformance phasing for EPS or margins in Q3 compared with Q4? Then, Liam, on the underlying business, I want to be certain I've got this right. My understanding is that you said the adjusted constant currency revenue guidance on an underlying basis, excluding the acquisition, remains the same. So I wonder whether you could say more about how you're viewing each of your businesses. It would help if you could point to any areas of upside versus downside relative to internal expectations.
Liam Kelly
executiveOf course, Shagun. I'll take the last part of your question, and then I'll have John address the first two components. As for our outlook, stepping back, we're very pleased with Q2. I believe we performed well in Q2. We reached some very important metrics; we met our revenue expectations. We came in above our margin and EPS, and I think we executed well and the team executed well during the quarter. To address your question, and you're exactly right, Shagun, with respect to our 2025 outlook, our underlying revenue guidance sees no change on that front. The sole difference is that we've included the BIOTRONIK Vascular Interventions business of $204 million in the second half, $99 million in Q3 and $105 million updates in Q4. Our revised revenue guidance is 7.7% to 8.7%. And clearly, we've raised our gross margin guidance by 50 basis points, and we've raised our EPS by $0.70. Now I'll have John once again walk through the breakup of that $0.70 and respond to the other part of your question.
John Deren
executiveRight. So once more, regarding that $0.70, roughly $0.50 of it ties back to tariffs, Shagun. And like Liam mentioned before, a portion of that comes from gains we achieved on the USMCA compliance and exemption side. But clearly, the changes in China and other places played a big role; so once more, Q2 saw no tariff effect since that effect didn't begin until the year's second half; and then — my apologies, you also want the gross margin side of those impacts, correct?
Shagun Singh Chadha
analystSo it's really just about how margins phase in over the back half?
Liam Kelly
executiveThe third and fourth quarters.
John Deren
executiveRegarding quarters 3 and 4, the effects from tariffs are pretty much the same, I'd say. For Q3, compared with Q4, we're probably a touch lower when you look at it from the beat standpoint. In Q4, we'll likely see a slight improvement, though I don't have — we don't have — providing a detailed breakout of margin between those two quarters isn't something we want to do.
Richard Newitter
analystI'd like to spend a moment on the Urology segment, returning to that CMS proposal. What I'm wondering is whether you could share your thinking on how it might affect the business, if it does at all? And is there a possible favorable effect on the standard of care? I'm aware there's been a shift away from the office setting for UroLift. Do you believe that could alter practice at the margin and assist that business in recovering somewhat?
Liam Kelly
executiveRich, I appreciate the question. Well, the revised CMS proposed rule — I want to emphasize that it remains a proposal. Should it take effect in the manner described, it would certainly be beneficial. Let me begin with Barrigel. For Barrigel on the office side of service, the uplift came to roughly 40%, while in the ASC you saw a 9% uplift, and 9% in the hospital too. Turning to UroLift, in the office it's about a 10% uplift. And actually it's 9% to 10% across every site of service for UroLift, uniformly; now, what that translates to in the office, Rich, to provide a bit of detail, is that it will almost — net of whatever rebates we'd have implemented. If you simply take the base reimbursement change, it would more than double the physician's fee, so to speak, net of the product cost on the office side of service. So we regard it as a favorable development; it's quite encouraging. And we'd also like to see it become — not remain a proposed rule, but become an actual rule, and we'll await that. And I believe, to CMS's credit, this reflects a really strong emphasis on shifting procedures from a costlier location to a cheaper one, such as the doctor's office, and we would strongly urge them to keep up that emphasis.
Richard Newitter
analystAnd then only one additional item. Intra-aortic balloon pumps appear to have been — that accounted for the bulk of the Interventional outperformance. Could you perhaps bring us up to date on your thinking regarding the sort of jump-all opportunity following a competitor issue, plus any refreshed views on what that might be, even looking ahead across the next 12 months?
Liam Kelly
executiveYes, Rich. In fact, the beat in Interventional versus our internal plan did not come from intra-aortic balloon pumps. The beat instead originated with OnControl and complex catheters. So the overall performance of that business left us very encouraged. Now, did balloons do well? Yes, they did well and landed very much where we expected. And in particular, the focus here is North America, and just as happened in Q1, we saw very strong double-digit growth in balloon pumps during Q2. On the outlook, we expect — as I mentioned earlier, we still expect the Interventional base business, excluding the BIOTRONIK Vascular Interventions business, to grow high single, low double digits for the year. Obviously, when you get specifically to balloon pumps, you run into a tougher comp in Q4. So my expectation is that growth from balloon pumps themselves will moderate once we reach Q4, since that was when the competitor's issue began; but taken altogether, we couldn't be more pleased with how our Interventional business performed, and the timing couldn't be better, because now we have the addition of the BIOTRONIK VI business into a business that's performing exceptionally well, and we're going through a separation at the same time. So all the stars seem to be aligning for that process.
Samantha Munoz
analystSamantha here, filling in for Matt this morning. What I'd like to know is whether you can share anything further regarding how things are going with the separation or the sale — when the announcement happened, was it a 50/50 split between a sale and a spin, and which way are you tilting at this point?
Liam Kelly
executiveAt the moment we made the announcement, we didn't actually express any tilt. In fact, at announcement, a spin was the only thing we put out there, and throughout the process, a substantial amount of inbound interest came our way. As I mentioned a bit earlier, the level of inbound interest we've gotten is encouraging to us. What I can share with the investment community is that unlocking shareholder value stays our focus. I can also say we've been putting in incredibly hard work; we aren't just sitting idle; and the biggest update we provided on this call, I'd say, is that numerous preliminary management meetings with interested parties have taken place. And we've done — as I mentioned a bit earlier — a great deal of work concerning the financial outlook for both businesses, pinpointing some of the key internal leadership who will head up the management presentations, many NDAs signed, which ought to speed up due diligence since that step alone can take just two weeks to complete. So putting these management meetings up front was, in fact, a smart strategic choice, because it propels us in the right direction. Whatever unlocks the greatest shareholder value is what we'll do. That's our North Star and the principle guiding us. And be it a sale or a spin, we have highly complex models running alongside independent third parties to help us navigate this; we know our tax basis. We understand really well what the spin would deliver to shareholders, so at this point it's simply a matter of working through the parallel path process and arriving at an outcome in our shareholders' best interest.
Samantha Munoz
analystGreat. And if I may quickly add one more thing regarding that proposed rule, particularly from CMS and Urology. I believe you mentioned that your elected figure sits at 9% to 10% in the office setting. I'm aware there was an expectation that your lot would return to growth next year on the back of these reimbursement changes? I simply want to verify whether that remains the current view.
Liam Kelly
executiveWell, Samantha, receiving a 10% uplift in the proposed rule is certainly going to support that hypothesis as we move toward 2026. Like I mentioned a bit earlier, and as everyone is aware, we've faced considerable pressure on the office side of service, that 10% lift would produce a good uptick from the — uptick for the physician; we'll work through this, and we'll collaborate with our customer base diligently to set up for improvements heading into 2026. But Samantha, you're absolutely correct; this is extremely encouraging; it's a proposed rule. My hope is that it becomes the rule at the start of the new year; and if that happens, it will certainly be more — it will certainly serve as a help rather than a hindrance to UroLift across all sites of service.
Mike Polark
analystI want to pick up that same topic, and regarding Barrigel, Liam, the office setting—or the increase being proposed for it—came across as quite meaningful. How is Barrigel's site of service mix split at present, and assuming a changed economic incentive, where do you believe it might land?
Liam Kelly
executiveMike, we don't provide a breakdown by site of service for Barrigel, though what I can say is that it reaches all three of those settings; and my sense is that the improvement across every site of service is quite heartening. My view is that over time the office gain could shift a portion of product into that setting. That alone gives us encouragement, since our call point into that site of service is very strong. And I genuinely believe it amounts to CMS acknowledging how crucial spacing is for men undergoing radiation therapy; and it's—my take is that it reflects what spacing delivers on that front.
Mike Polark
analystThat's useful. If I could ask a second question, perhaps directed at John. John, my recollection is that during the portion on ways to lessen tariff effects, you said that as agreements reach their renewal dates, you'd seek to put through higher prices for customers, aiming to counter a portion of the squeeze caused by tariffs. Do you have any initial sense of how that might play out? What I mean is, I realize the sector at large will likely pursue something along these lines. Over the past 2 years, following the inflation surge of the COVID period, hospitals appear to have accepted upward price changes. I'm simply wondering whether you believe the reaction will be comparable when it comes to tariffs, or whether you're already picking up on any resistance on that side. Thanks for whatever you can share about it.
John Deren
executiveYes. What I'd say is that we are definitely at an early point. For 2025, we don't anticipate a large effect. Once we reach our 2026 guidance, we'll be in a position to provide somewhat more direction regarding how we see that year shaping up. We hold a perspective on where we believe we could raise price where it makes sense, and that applies not only within the United States but in other regions too, and certain timing factors will mean it happens somewhat more gradually than we'd prefer. Still, my sense is that 2026 will truly be the bigger chance. Regarding what we intend to put forward, I would not anticipate meaningful resistance.
Mike Matson
analystNow that the BIOTRONIK deal has closed, could you share some perspective on how the sales teams will be brought together? What's the degree of overlap with the Interventional sales force that already exists? What timeline do you anticipate for the integration work? And how much disruption risk is involved?
Liam Kelly
executiveYes. Of course, Mike. I appreciate the question. When you examine how the BIOTRONIK VI revenue splits up, roughly 50% comes from EMEA, 25% from the Americas, and 25% from APAC. That distribution alone creates a major chance to push faster revenue growth by making use of those channels. Looking at our own business, we're far stronger in the Americas, we have a solid business in Europe, and we're weaker in Asia Pacific. So this presents an opportunity, as I mentioned a bit earlier, to assist in securing cath lab access for BIOTRONIK products in the Americas. It also leverages the BIOTRONIK organization's strength in EMEA to combine that with the product portfolio. The result will be a bigger sales force everywhere selling our entire range of products into these markets, and we genuinely see a chance for revenue synergies to be generated by bringing these two businesses together.
Mike Matson
analystAlright, understood. Then I have a single question regarding Titan. What have you been observing lately when it comes to bariatric surgery? Are volumes continuing to fall in that area? To be more precise, how is Titan performing? I realize it's likely outperforming the broader bariatric volume trends, since it's somewhat of a market penetration situation, but...
Liam Kelly
executiveCorrect, Mike. We still anticipate double-digit growth for this year as we keep gaining share. However, we are observing a downturn in bariatric surgery across the market; the effect of GLP-1s is obviously making a difference there. Yet that only affects how our product impacts the margins as we keep penetrating the market. I believe the clinical evidence we've been producing is genuinely valuable, since we can demonstrate a reduction incurred; we can also demonstrate a shorter hospital stay along with clinical outcomes that are equal or even superior after the procedure. It remains the sole single-line staple product available on the market, which achieves symmetry of outcomes for gastric sleeves and bariatric surgery; so we continue to feel encouraged by Titan's performance; however, you're right, that market faces pressure owing to the rollout of GLP-1s.
Larry Keusch
executiveSarah, thanks — and thanks as well to each of you who took part in today's call. That wraps up the Teleflex Inc. Second Quarter 2025 Earnings Conference Call.
Operator
operatorThank you. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.